We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01472419
First Posted: November 16, 2011
Last Update Posted: April 9, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
November 11, 2011
November 16, 2011
April 9, 2013
March 2012
December 2012   (Final data collection date for primary outcome measure)
Overall Survival [ Time Frame: 12 month ]
Same as current
Complete list of historical versions of study NCT01472419 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients
Esophageal squamous cell carcinoma is considerably more prevalent in East Asia. Despite of relatively high prevalence of esophageal SCC, prognosis is very poor with limited options of effective chemotherapy regimens. We attempted to identify favorable subgroups of patient who are likely to benefit from 5- fluorouracil/cisplatin(FP) or capecitabine/cisplatin (XP) chemotherapy as first-line treatment.Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy. Clinicopathologic variables and treatment outcome were retrospectively collected. we analysis treatment outcome of palliative chemotherapy in metastatic esophageal squamous cell carcinoma and make prognostic scoring system. The present study represents the largest series to analyze the treatment outcome of FP/XP chemotherapy in metastatic SCC. Risk-adapted stratification of treatment for subgroup of metastatic SCC patients should be actively pursued.
Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy.
Metastatic Esophageal Squamous Cell Carcinoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
239
March 2013
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • recurrent, metastatic esophageal SCC
  • received either FP or XP as first-line chemotherapy.

Exclusion Criteria:

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01472419
SMCESOPROGNOSIS
No
Not Provided
Not Provided
Jeeyun Lee, Samsung Medical Center
Samsung Medical Center
Not Provided
Principal Investigator: Jeeyun Lee, M.D., Ph.D. Samsung Medical Center, Seoul, Korea
Samsung Medical Center
April 2013